Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Seres Therapeutics, Inc. filings document the disclosure record of a Nasdaq-listed biotechnology company focused on live biotherapeutic and microbiome-based therapeutic programs. Its Form 8-K reports furnish quarterly and annual financial results, operational updates, Regulation FD corporate presentations, and material-event disclosures involving pipeline priorities, clinical and regulatory matters, capital allocation, cost-reduction actions, and financing or partnership activity.
The company’s proxy materials cover annual meeting mechanics, stockholder voting, board governance, executive compensation, and equity-award information. SEC filings also identify Seres’ common stock registered under the Exchange Act and traded on the Nasdaq Global Select Market under the symbol MCRB.
Seres Therapeutics, Inc. director Kurt Graves received a grant of stock options to acquire 6,500 shares of common stock at an exercise price of $7.14 per share. The options expire on July 7, 2036 and vest on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026.
Seres Therapeutics, Inc. reported that director and officer Richard N. Kender received a grant of stock options covering 50,000 shares of common stock at an exercise price of $9.13 per share. These options vest in 36 equal monthly installments beginning on March 2, 2026, and are scheduled to expire on March 3, 2036. Following this grant, Kender holds stock options for 50,000 shares directly.
Seres Therapeutics, Inc. reported that officer Matthew R. Henn received a grant of stock options for 25,000 shares of common stock. The options carry an exercise price of $9.13 per share and expire on March 3, 2036. According to the vesting terms, 25% of the options vest on March 2, 2027, with the remaining shares vesting in 12 equal quarterly installments thereafter, contingent on continued service.
Seres Therapeutics, Inc. reported that company officer Marella Thorell received a compensatory grant of stock options covering 7,500 shares of common stock at an exercise price of $9.13 per share. The options were awarded at no cost and will vest as to 25% of the shares on March 2, 2027, with the remaining shares vesting in 12 equal quarterly installments thereafter, subject to continued service.
Seres Therapeutics, Inc. reported that director Claire Fraser received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share. The options expire on July 7, 2036 and vest and become exercisable on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026. Following this award, Fraser holds options for 6,500 shares directly.
Seres Therapeutics, Inc. director Willard H. Dere received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share. The options vest and become exercisable on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026, and expire on July 7, 2036. Following this award, Dere holds options for 6,500 shares directly.
Seres Therapeutics, Inc. director Dennis A. Ausiello received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share. The options vest and become exercisable on the earlier of July 8, 2027 or the day immediately prior to the first annual stockholder meeting occurring after July 8, 2026, and expire on July 7, 2036. Following this grant, he holds 6,500 derivative securities directly.
Seres Therapeutics, Inc. director Eric D. Shaff received a grant of stock options covering 6,500 shares of common stock. The options have an exercise price of $7.14 per share and expire on July 7, 2036. Vesting occurs on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026.
Seres Therapeutics, Inc. reported that director Robert L. Rosiello received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share. These options vest and become exercisable on the earlier of July 8, 2027 or the day immediately before the first annual stockholder meeting occurring after July 8, 2026, and expire on July 7, 2036. Following this grant, Rosiello holds 6,500 derivative securities directly.
Seres Therapeutics, Inc. director Stephen Berenson received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share. These options vest and become exercisable on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026, and expire on July 7, 2036. Following this grant, he holds 6,500 derivative securities directly.